The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Abstract
A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been shown to improve progression-free survival when added to standard chemotherapy regimens for lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,008
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70002-0 · Cited by 1,130
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
van Oers, M. H. J., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., van't Veer, M., Vranovsky, A., Holte, H., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021113 · Cited by 592
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2493 · Cited by 581
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Rituximab: A Review of its Use in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukaemia
Plosker, G. L., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363080-00005 · Cited by 471
Tolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., Diaz, M. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2015 · Cited by 460
Schulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk152 · Cited by 362
van Oers, M. H. J., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5827 · Cited by 328
Persky, D. O., Unger, J. M., Spier, C. M., Stea, B., LeBlanc, M., McCarty, M. J., Rimsza, L. M., Fisher, R. I., & Miller, T. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6929 · Cited by 294
Brennan, P. J., Bouza, T. R., Hsu, F. I., Sloane, D. E., & Castells, M. C. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.009 · Cited by 283
Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M., & Fisher, R. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8198 · Cited by 280
Self-citationMouse CD20 expression and function
Uchida, J. (2004) · International Immunology · doi:10.1093/intimm/dxh009 · Cited by 244
Wallace, P., Barber, J., Clayton, W., Currell, R., Fleming, K., Garner, P., Haines, A., Harrison, R., Jacklin, P., Jarrett, C., et al. (2004) · Health Technology Assessment · doi:10.3310/hta8500 · Cited by 237
Tedder, T. F., Streuli, M., Schlossman, S. F., & Saito, H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.1.208 · Cited by 216
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Beers, S. A., Chan, C. H. T., French, R. R., Cragg, M. S., & Glennie, M. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.001 · Cited by 209
Wilson, W. H., Jung, S.-H., Porcu, P., Hurd, D., Johnson, J., Martin, S. E., Czuczman, M., Lai, R., Said, J., Chadburn, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.056531 · Cited by 167
Wolach, O., Bairey, O., & Lahav, M. (2010) · Medicine · doi:10.1097/md.0b013e3181f2caef · Cited by 158
Non-infectious pulmonary toxicity of rituximab: a systematic review
Hadjinicolaou, A. V., Nisar, M. K., Parfrey, H., Chilvers, E. R., & Östör, A. J. K. (2011) · Rheumatology · doi:10.1093/rheumatology/ker290 · Cited by 154
Dreyling, M. H., Ghielmini, M. E. G., Marcus, R. E., Salles, G., & Vitolo, U. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr388 · Cited by 130
Mice carrying a CD20 gene disruption
O’Keefe, T. L., Williams, G. T., Davies, S. L., & Neuberger, M. S. (1998) · Immunogenetics · doi:10.1007/s002510050412 · Cited by 129
Hepatitis B reactivation after chemotherapy: two decades of clinical research
Lau, G. K. K. (2008) · Hepatology International · doi:10.1007/s12072-008-9056-3 · Cited by 121
Stevens–Johnson syndrome after treatment with rituximab
Lowndes, S. A., Darby, A., Mead, G. M., & Lister, A. T. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf350 · Cited by 120
Weng, W., Negrin, R. S., Lavori, P. W., & Horning, S. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0274 · Cited by 93
Robak, T. (2009) · PubMed · Cited by 87
Tilly, H., & Dreyling, M. H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq203 · Cited by 71
Hornberger, J. C., & Best, J. H. (2005) · Cancer · doi:10.1002/cncr.20956 · Cited by 66
Knight, C., Hind, D., Brewer, N., & Abbott, V. (2004) · Health Technology Assessment · doi:10.3310/hta8370 · Cited by 54
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70054-2 · Cited by 51
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.23803 · Cited by 45
Cited by
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 504
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 393
Viardot, A., Goebeler, M.-E., Hess, G., Neumann, S., Pfreundschuh, M., Adrian, N., Zettl, F., Libicher, M., Sayehli, C., Stieglmaier, J., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651380 · Cited by 378
Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70122-0 · Cited by 304
Metadata
- Authors
- Maloney, D. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-24
- Volume
- 366
- Issue
- 21
- Pages
- 2008-2016
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2055886080
- Cited by
- 322
- References
- 52
- FWCI
- 26.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.